Discover how the groundbreaking mRNA-HPV vaccine targeting E6 and E7 proteins offers new hope for treating HPV-related cancers through a simple subcutaneous immunization approach.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization.
Lee et al., J Med Virol 2023
DOI: 10.1002/jmv.29309
Listen, folks, we’ve got something incredible here, it’s just fantastic. We’re talking about a vaccine, a messenger RNA-HPV therapeutic vaccine, and let me tell you, it’s not just any vaccine. It’s targeting those nasty HPV proteins, E6 and E7, you know, the ones causing cervical cancer. And we’re not talking about small-time HPV types; we’re hitting the big ones, HPV 16 and 18.
So, we took these amazing mice, the best mice, C57BL/6j, and we gave them this vaccine. We did it the right way, both intramuscular and subcutaneous, because we don’t mess around. And the results? Phenomenal. We’re seeing huge T cell responses, and these tumors? They’re shrinking, they’re practically disappearing in these mice. It’s like nothing you’ve ever seen.
And get this, we even tried to bring the tumors back, but guess what? They couldn’t. Not after our vaccine. It’s that good. We’re talking 100% effectiveness here. Even after a long time, the tumors just couldn’t take it. This vaccine is a winner.
But we didn’t stop there. No, we went bigger. We tested on rhesus monkeys, and the results? Outstanding. If it works on monkeys, we’re talking about a game-changer for humans, for you and me.
So, what we’ve got here is a vaccine that’s not just therapeutic, it’s prophylactic too. It’s a two-in-one. It’s going to change the game in the fight against HPV-related cancers. Believe me, it’s going to be huge.